IQVIA™ Real-World Insights Bibliography

Two-year adherence and costs for biologic therapy for rheumatoid arthritis
Author(s): Stolshek BS, Wade S, Mutebi A, De AP, Wade RL, Yeaw J
Affiliations(s): Amgen, IQVIA
Publication(s):  Am J Manag Care
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C:
Y:
Rheumatology,
2018
  L:
A:
English
Cost analysis, Retrospective cohort analysis,
  Add to report
 
 
Assessing Treatment Tolerability for Rheumatoid Arthritis. Validation and Practical Applications of the ‘TOL-AR-18 Questionnaire
Author(s): Corominas H, Espadaler L, Gómez A, Ros I, Urruticoechea A, Sarmiento M, Sanmartí R
Affiliations(s): Corominas H.: Rheumatology and Autoimmune diseases Division, Hospital Universitari de Sant Pau & Hospital Dos de Maig, Barcelona, Spain Sarmiento M: Real-World Evidence Solutions, IMS Health, Spain
Publication(s):  Reumatología Clínica 2018; Sep 5. [Epub ahead of print]
Document Type(s): Article,
Countries: Spain,
Click here for the abstract
C:
Y:
Health status & patient reported outcomes, Rheumatology,
2018
  L:
A:
English
Clinical setting: hospital, Observational study,
  Add to report
 
 
Canadian Study of Adherence Outcomes in HUMIRA® (Adalimumab) Patients – Three-Year Results from the COMPANION Study in Rheumatology Patients
Author(s): Bessette L1, Millson B2, Sung M2, Gaetano T3, Latour M3, Laliberté MC3
Affiliations(s): 1 Department of Medicine, Laval University, Quebec City, Quebec, Canada 2 IMS Brogan, Kirkland, Quebec, Canada; 3AbbVie Corporation, St. Laurent, Quebec, Canada
Publication(s):  Canadian Rheumatology Association 2017 Scientific Meeting, February 8-11, Ottawa, Canada
Document Type(s): Poster,
Countries: Canada,
Click here for the abstract
C:
Y:
Rheumatology,
2017
  L:
A:
English
Database Study,
  Add to report
 
 
Regional policies impact on biosimilar adoption for autoimmune diseases in Italy
Author(s): Tucci C1, Rova A1, Mantuano M1, Tettamanti A1
Affiliations(s): QuintilesIMS, Milan, Italy
Publication(s):  ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
Document Type(s): Poster,
Countries: Italy,
C:
Y:
Dermatology, Gastrointestinal disorders, Health policy, Rheumatology,
2017
  L:
A:
English
Literature Review,
  Add to report
 
 
Market share and switching dynamics between Etanercept and its biosimilar product in Sweden and Germany: a real-world preliminary analysis.
Author(s): Alten R1, Neregård P2, Jones HE3, Meng T4, Curiale C5, Singh E6, Lucchese L7, Gossen N8, Bergman GJ9, Miglio C7
Affiliations(s): 1 Shlosspark-Klinik Teaching Hospital of the Charité, Berlin, Germany 2 Pfizer, Sollentuna, Sweden 3 Pfizer inc., Collegeville, PA, USA 4 Pfizer Pharma GmbH, Berlin, Germany 5 Pfizer, Rome, Italy 6 Pfizer Inc., Collegeville, PA, USA 7 QuintilesIMS, London, UK 8 QuintilesIMS, Frankfurt, Germany 9 QuintilesIMS, Solna, Sweden
Publication(s):  ISPOR 20th Annual European Congress
Document Type(s): 
Countries: Germany, Sweden,
Click here for the abstract
C:
Y:
Immunology and Vaccination, Patient Registries & Real-World Study Methods, Rheumatology,
2017
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
Depression risk in patients with rheumatoid arthritis in the United Kingdom
Author(s): Jacob L,Rockel T, Kostev K
Affiliations(s): 
Publication(s):  Rheumatol Ther. 2017 Mar 20. doi: 10.1007/s40744-017-0058-2. [Epub ahead of print]
Document Type(s): Article,
Countries: UK,
C:
Y:
Mental health, Rheumatology,
2017
  L:
A:
English
  Add to report
 
 
COMMONALITIES AND DIFFERENCES IN DATA COLLECTION ACROSS EUROPEAN SPONDYLOARTHRITIS REGISTRIES
Author(s): M. L. Hetland* 1, M. Østergaard1, J. Askling2, C. Gabay3, D. Nordstrom4, O. FitzGerald5, M. Hernández Miguel6, M. Santos7 , Z. Rotar8, H. Mann9, F. Iannone10, M. J. Nissen3, E. Hauge1, J. Gomez-Reino11, F. Díaz-González12, M. Tomsic8, K. Pavelka9, F. O'Shea5, C. Sullivan5, M. van de Sande13, I. E. van der Horst-Bruinsma13, G. J. Macfarlane14, G. T. Jones14, B. Gudbjørnsson15, T. K. Kvien16 on behalf of EuroSpA Study Group
Affiliations(s): 1DANBIO, Glostrup, Denmark, 2ARTIS, Stockholm, Sweden, 3SCQM, Geneva, Switzerland, 4ROB-FIN, Helsinki, Finland, 5ASRI, Dublin, Ireland, 6BIOBADASER, Barcelona, Spain, 7reuma.pt, Almada, Portugal, 8biorx.si, Ljubljana, Slovenia, 9ATTRA, Prague, Czech Republic, 10GISEA, Bari, Italy, 11BIOBADASER, Santiago, 12BIOBADASER, Santa Cruz de Tenerife, Spain, 13ARC, Amsterdam, Netherlands, 14BSRBR-AS, Aberdeen, United Kingdom, 15ICEBIO, Reykjavik, Iceland, 16NORDMARD, Oslo, Norway
Publication(s):  EULAR, Madrid, 2017
Document Type(s): Abstract,
Countries: Czech, Denmark, Finland, Ireland, Italy, Norway, Slovenia, Spain, Sweden, Switzerland,
Click here for the abstract
C:
Y:
Rheumatology,
2017
  L:
A:
English
Epidemiological study,
  Add to report
 
 
Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Author(s): Lyu R1, Govoni M2, Ding Q1, Black CM3, Kachroo S4, Fan T1, Ogbonnaya A5, Donga P5, Hill J5, Makin C5.
Affiliations(s): 1Merck Co., Inc, Whitehouse Station, NJ, USA. 2MSD Italy, Rome, Italy. 3Merck Co., Inc, 126 E. Lincoln Avenue, Mail code: RY32-211, Rahway, NJ, 07065, USA. 4Merck Co., Inc, 126 E. Lincoln Avenue, Mail code: RY32-211, Rahway, NJ, 07065, USA. sumesh.kachroo@merck.com. 5IMS Health, Alexandria, VA, USA.
Publication(s):  Rheumatol Int. 2016 Jan;36(1):143-53.
Document Type(s): Article,
Countries: Germany,
Click here for the abstract
C:
Y:
Rheumatology,
2016
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
Canadian Study of Outcomes in HUMIRA® (Adalimumab) Patients with Support for Adherence - Results from the COMPANION Study
Author(s): Gerega S1, Millson B1, Bessette L2, Marshall JK3, Lebovic G4,5, Sung M1, Oraichi D1, Gaetano T6, Gazel S6, Latour M6, Laliberté MC6
Affiliations(s): 1 IMS Brogan, Kirkland, Quebec, Canada 2 Department of Medicine, Laval University, Quebec City, Quebec, Canada 3 Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, Ontario, Canada 4 Applied Health Research Centre, St. Michael’s Hospital, Toronto, Ontario, Canada 5 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada 6 AbbVie Corporation, St. Laurent, Quebec, Canada
Publication(s):  American College of Rheumatology 2016 Annual Meeting, November 11-16, Washington DC, USA
Document Type(s): Poster,
Countries: Canada,
Click here for the abstract
C:
Y:
Medication compliance, Rheumatology,
2016
  L:
A:
English
Database Study,
  Add to report
 
 
Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis.
Author(s): Morlock R1, Chevalier P2, Horne L3, Nuevo J4, Storgard C1, Aiyer L1, Hines DM5, Ansolabehere X6, Nyberg F7,8
Affiliations(s): 1 Ardea Biosciences, San Diego, CA, USA 2 IMS Health HEOR, Zaventem, Belgium 3 AstraZeneca, Wilmington, DE, USA 4 AstraZeneca, Madrid, Spain 5 IMS Health HEOR, Fairfax, VA, USA, 6 IMS Health HEOR, Paris, France, 7 AstraZeneca, Mölndal, Sweden 8 University of Gothenburg, Gothenburg, Sweden
Publication(s):  Rheumatol Ther., 2016, 3(1): 53-75
Document Type(s): Article,
Countries: France, Germany, UK, USA,
C:
Y:
Rheumatology,
2016
  L:
A:
English
  Add to report
 
 
 1 of 10 Next Page Last Page